

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. **(Currently Amended)** A method of selectively reducing the number or activity of macrophages within a localized area of tissue, comprising contacting the area of tissue with a macrophage-binding compound comprising (a) a first agent which is an antibody or binding fragment thereof which binds to an Fc receptor ~~at a site which is distinct from that bound by endogenous immunoglobulins~~; and (b) a second agent which kills or reduces the activity of the macrophages, wherein the first and second agents are different, and wherein the macrophage-binding compound is administered topically, intradermally or subcutaneously in a pharmaceutically acceptable carrier.

2. **(Currently Amended)** A method of treating a disease in a subject characterized by aberrant activity or numbers of macrophages within a selected area of the subject, comprising locally administering to the area a macrophage-binding compound comprising (a) a first agent which is an antibody or binding fragment thereof which binds to an Fc receptor; and (b) a second agent which kills or reduces the activity of the macrophages, wherein the first and second agents are different, and wherein the macrophage-binding compound is administered topically, intradermally or subcutaneously in a pharmaceutically acceptable carrier.

3. **(Currently Amended)** The method of claim 1 or 2, wherein the agent antibody which binds to an Fc receptor binds at a site which is ~~not bound by an endogenous immunoglobulin~~ not blocked by the natural ligand.

4. **(Original)** The method of either of claims 1 or 2, wherein the Fc receptor is an Fc γ receptor (Fc γ R) or an Fc α receptor (Fc α R).

5. **(Original)** The method of claim 4, wherein the Fc γ receptor is selected from the group consisting of Fc γ RI, Fc γ RII and Fc γ RIII.
6. **(Original)** The method of claim 5, wherein the Fc γ receptor is a human Fc γ RI.
7. **(Original)** The method of claim 4, wherein the Fc receptor is a human Fc α R.
8. **(Original)** The method of either of claims 1 or 2, wherein the macrophage-binding compound comprises an anti-Fc receptor antibody conjugated to a toxin.
9. **(Original)** The method of claim 8, wherein the anti-Fc receptor antibody is an anti-Fc γ receptor antibody or a fragment thereof.
10. **(Currently Amended)** The method of claim 9, wherein the anti-Fc γ receptor antibody is a monoclonal antibody selected from the group consisting of mab 22, or a fragment thereof, having ATCC accession number HB-12147, and mab 32, or a fragment thereof, having ATCC accession number HB9469, and 197, or a fragment thereof.
11. **(Original)** The method of claim 9, wherein the anti-Fc γ receptor antibody is a humanized antibody H22 produced by the cell line having ATCC accession number CRL 1117 or a fragment thereof.
12. **(Original)** The method of claim 8, wherein the toxin is selected from the group consisting of Gelonin, Saporin, Exotoxin A, Onconase and Ricin A.
13. **(Original)** The method of claim 1, wherein the agent which kills or reduces the activity of the macrophages is encapsulated within a liposome.

14. **(Original)** The method of claim 13, wherein the agent which kills or reduces the activity of a macrophage is dichloromethylene diphosphonate (CL2MDP) or a derivative thereof.

15. **(Currently Amended)** The method of claim 13, wherein the ~~agent~~ antibody which binds to an Fc receptor is a single chain antibody.

16. **(Currently Amended)** The method of claim 13, wherein the ~~agent~~ antibody which binds to an Fc receptor is an anti-Fcγ receptor antibody or a fragment thereof.

17. **(Currently Amended)** The method of claim 13, wherein the ~~agent~~ antibody which binds to an Fc receptor is a single chain anti-Fcγ receptor antibody or a fragment thereof.

18. **(Original)** The method of claim 1, wherein the contacting step occurs in culture.

19. **(Original)** The method of claim 2, wherein the disease is characterized by enhanced proliferation and/or growth factor secretion of the macrophage.

20. **(Original)** The method of claim 2, wherein the disease is selected from the group consisting of psoriasis, atopic dermatitis, scleroderma, cutaneous lupus erythematosus, Human Immunodeficiency Virus infection, multiple sclerosis, rheumatoid arthritis, Chronic Polymorphic Light Dermatitis, Chronic Obstructive Pulmonary Diseases, and Wegener's Granulomatosis.

21. **(New)** The method of claim 1 or 2, wherein the compound further comprises a photosensitizing moiety.